85 related articles for article (PubMed ID: 7600031)
1. Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer.
Miller AA; Niell HB; Griffin JP
Lung Cancer; 1995 Mar; 12(1-2):59-65. PubMed ID: 7600031
[TBL] [Abstract][Full Text] [Related]
2. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer.
Miller AA; Tolley EA; Niell HB; Griffin JP; Mauer AM
J Clin Oncol; 1993 Jun; 11(6):1179-88. PubMed ID: 8388920
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
7. Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
Comella P; Scoppa G; Daponte A; Musetta G; Anania C; Maiorino A; Curcio C; Casaretti R; Comella G
Cancer; 1994 Oct; 74(7):1874-81. PubMed ID: 8082093
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
Cancer Chemother Pharmacol; 1997; 40(4):347-52. PubMed ID: 9225954
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung cancer.
Ali MA; Kraut MJ; Valdivieso M; Wozniak AJ; Cummings G; Kalemkerian GP
Cancer Invest; 2000; 18(1):1-5. PubMed ID: 10701360
[TBL] [Abstract][Full Text] [Related]
12. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
13. Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
Martoni AA; Melotti B; Sperandi F; Giaquinta S; Piana E; Pavesi L; Da Prada G; Lelli G
Lung Cancer; 2008 Jun; 60(3):387-92. PubMed ID: 18160123
[TBL] [Abstract][Full Text] [Related]
14. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report.
Shepherd FA; Goss PE; Latreille J; Stewart D; Logan D; Evans WK; Maroun J; Warner E
Semin Oncol; 1990 Apr; 17(2 Suppl 4):19-23. PubMed ID: 2159185
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
[TBL] [Abstract][Full Text] [Related]
17. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.
Font A; Moyano AJ; Puerto JM; Tres A; Garcia-Giron C; Barneto I; Anton A; Sanchez JJ; Salvador A; Rosell R
Cancer; 1999 Feb; 85(4):855-63. PubMed ID: 10091762
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
Georgoulias V; Androulakis N; Dimopoulos AM; Kourousis C; Kakolyris S; Papadakis E; Apostolopoulou F; Papadimitriou C; Vossos A; Agelidou M; Heras P; Tzannes S; Vlachonicolis J; Mavromanolakis E; Hatzidaki D
Ann Oncol; 1998 Mar; 9(3):331-4. PubMed ID: 9602269
[TBL] [Abstract][Full Text] [Related]
19. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study.
Scinto AF; Ferraresi V; Milella M; Tucci E; Santomaggio C; Pasquali-Lasagni R; Del Vecchio MR; Campioni N; Nardi M; Cognetti F
Br J Cancer; 1999 Nov; 81(6):1031-6. PubMed ID: 10576661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]